EAACI Congress 2025
BackFT09 - Allergen immunotherapy in clinical studies
Saturday 14 Jun, 13:15 PM -
14:45 PM Glasgow, United Kingdom
Dochart 2
Flash Talks
13:15
Relevant patient benefit in the short-term with a 300IR dosing pump-administered liquid sublingual immunotherapy: Results from the observational, prospective, longitudinal PRACTIS study
13:22
Dietary outcomes following oral immunotherapy for cows milk allergy: Results from the SOCMA Study
13:29
Randomized controlled trial of pancake oral immunotherapy for egg allergy
13:36
Two-year Outcomes of Low-dose Oral Immunotherapy for Children with Severe Walnut Allergy
13:43
Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics of IGNX001 in Peanut-Allergic (PA) Adults and Older Adolescents - Day 8 Safety Data for Cohort 1 of the ACCELERATE Peanut Study
13:50
Positive effect of a 300IR dosing pump-administered liquid sublingual immunotherapy on allergic disease evolution: Results from the observational, prospective, longitudinal PRACTIS study
13:57
Study design for compaRison of onset time of therapeutic effects between the one-strength Accelerated dose-escalation and conventional scheme for SCIT with a native HDM allergen Preparation in chIldren and aDolescents with allergic rhinitis (RAPID Study)
14:04
SQ tree SLIT-tablet is well tolerated in children with tree pollen allergic rhinitis and/or conjunctivitis in the TT-06 phase III trial
14:11
Consistent efficacy of the SQ HDM SLIT-tablet in children (5–11 years) with house dust mite allergic rhinitis/rhinoconjunctivitis across subgroups in the MT-12 phase III trial
14:18
The safety of an optimal accelerated immunotherapy for allergic rhinitis in adolescent and adult patients in China (PERFECT study)
14:25
Safety of the SQ HDM SLIT-tablet in children (5–11 years) with house dust mite allergic rhinitis/rhinoconjunctivitis in the MT-12 phase III trial
